Literature DB >> 20051532

Regulation of multidrug resistance protein 1 by tumor necrosis factor alpha in cultured glial cells: involvement of nuclear factor-kappaB and c-Jun N-terminal kinase signaling pathways.

Patrick T Ronaldson1, Tamima Ashraf, Reina Bendayan.   

Abstract

Pharmacotherapy of brain HIV-1 infection may be limited by ABC transporters [i.e., P-glycoprotein (P-gp), multidrug resistance protein 1 (Mrp1)] that export antiretroviral drugs from HIV-1 brain cellular targets (i.e., astrocytes, microglia). Using an in vitro astrocyte model of an HIV-1 associated inflammatory response, our laboratory has shown that cytokines [i.e., tumor necrosis factor alpha (TNF-alpha), interleukin (IL)-1 beta, IL-6], which are secreted in response to HIV-1 envelope glycoprotein gp120 exposure, can decrease P-gp functional expression; however, it is unknown whether these same cytokines can alter expression and/or activity of other ABC transporters (i.e., Mrp1). In primary cultures of rat astrocytes, Mrp1 expression was increased by TNF-alpha (2.7-fold) but was not altered by IL-1 beta or IL-6. Cellular retention of 2',7'-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein, an Mrp substrate, was reduced in TNF-alpha-treated astrocytes, suggesting increased Mrp-mediated transport. Pharmacologic inhibition of nuclear factor-kappaB (NF-kappaB) signaling with SN50 prevented both TNF-alpha release and Mrp1 expression changes in astrocytes triggered with gp120; however, SN50 did not attenuate Mrp1 expression in cells triggered with TNF-alpha. In contrast, Mrp1 functional expression was not altered in the presence of gp120 or TNF-alpha when astrocyte cultures were pretreated with 1,9-pyrazoloanthrone (SP600125), an established c-Jun N-terminal kinase (JNK) inhibitor. SP600125 did not affect TNF-alpha release from cultured astrocytes triggered with gp120. Mrp1 mRNA expression was increased after treatment with gp120 (1.6-fold) or TNF-alpha (1.7-fold), suggesting altered Mrp1 gene transcription. These data suggest that gp120 and TNF-alpha can up-regulate Mrp1 expression in cultured astrocytes. Furthermore, our results imply that both NF-kappaB and JNK signaling are involved in Mrp1 regulation during an HIV-1 associated inflammatory response.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20051532     DOI: 10.1124/mol.109.059410

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  24 in total

Review 1.  Targeting blood-brain barrier changes during inflammatory pain: an opportunity for optimizing CNS drug delivery.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Ther Deliv       Date:  2011-08

Review 2.  Blood-brain barrier integrity and glial support: mechanisms that can be targeted for novel therapeutic approaches in stroke.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

3.  HIV-1 Alters Intestinal Expression of Drug Transporters and Metabolic Enzymes: Implications for Antiretroviral Drug Disposition.

Authors:  Olena Kis; Sumathi Sankaran-Walters; M Tozammel Hoque; Sharon L Walmsley; Satya Dandekar; Reina Bendayan
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

4.  Cross-talk between neurons and astrocytes in response to bilirubin: adverse secondary impacts.

Authors:  Ana Sofia Falcão; Rui F M Silva; Ana Rita Vaz; Cátia Gomes; Adelaide Fernandes; Andreia Barateiro; Claudio Tiribelli; Dora Brites
Journal:  Neurotox Res       Date:  2014-07       Impact factor: 3.911

5.  Regulation of P-glycoprotein by human immunodeficiency virus-1 in primary cultures of human fetal astrocytes.

Authors:  Tamima Ashraf; Patrick T Ronaldson; Yuri Persidsky; Reina Bendayan
Journal:  J Neurosci Res       Date:  2011-08-08       Impact factor: 4.164

Review 6.  JNK signalling in cancer: in need of new, smarter therapeutic targets.

Authors:  Concetta Bubici; Salvatore Papa
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

7.  Resveratrol reverses P-glycoprotein-mediated multidrug resistance of U2OS/ADR cells by suppressing the activation of the NF-κB and p38 MAPK signaling pathways.

Authors:  Rui Zhang; Ming Lu; Zhen Zhang; Xiliang Tian; Shouyu Wang; Decheng Lv
Journal:  Oncol Lett       Date:  2016-09-14       Impact factor: 2.967

8.  In vivo and ex vivo regulation of breast cancer resistant protein (Bcrp) by peroxisome proliferator-activated receptor alpha (Pparα) at the blood-brain barrier.

Authors:  Md Tozammel Hoque; Arpit Shah; Vijay More; David S Miller; Reina Bendayan
Journal:  J Neurochem       Date:  2015-11-13       Impact factor: 5.372

9.  Solanine reverses multidrug resistance in human myelogenous leukemia K562/ADM cells by downregulating MRP1 expression.

Authors:  Ying-Jie Yi; Xiu-Hong Jia; Cong Zhu; Jian-Yong Wang; Jie-Ru Chen; Hong Wang; You-Jie Li
Journal:  Oncol Lett       Date:  2018-04-25       Impact factor: 2.967

Review 10.  Targeted drug delivery to treat pain and cerebral hypoxia.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Pharmacol Rev       Date:  2013-01-23       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.